A multiple-dose, phase Ib study of KL-1333 in US/European population.
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs KL 1333 (Primary)
- Indications Mitochondrial disorders
- Focus Adverse reactions
- Sponsors NeuroVive Pharmaceutical
- 15 Feb 2018 According to a NeuroVive Pharmaceuticals media release, the proceeds from a successful Rights issue will be used for clinical development and start of this trial in 2018.
- 04 Jul 2017 New trial record
- 27 Jun 2017 According to a NeuroVive Pharmaceutical media release, the company plans to initiate this study in early 2018.